A simple word lookup for cannabinoid research.
Look Up A Word
Cannabinoid Dictionary
Look up cannabinoid words, aliases, receptors, health topics, safety terms, and research-language terms. Start here when a page uses a word you do not know.
Search or scan the A-Z list. Open a term to see the simple definition and related source-backed pages.
Definitions help you understand the words. They are not proof by themselves.
Dictionary entries resolve to plain-language definitions, related source-backed pages, and methodology context. The definitions are navigation aids; source-backed claims stay on the evidence pages.
How To Use The Dictionary
Start with a term, then open the evidence trail.
- Define the word.Read the plain-language meaning and category.
- Check the evidence lens.Look for exact evidence rows, related pages, and source counts.
- Follow citations.Use related pages and exact rows for PubMed or DOI-backed claims.
Evidence Vocabulary By Category
The dictionary is organized by reading job.
Evidence labels explain what kind of source is being read.
1285 exact rows / 938 sourcesMechanism terms explain biological plausibility and target language.
9 exact rows / 5 sourcesPharmacology terms describe exposure, action, metabolism, and interpretation.
24 exact rows / 18 sourcesProduct terms keep extracts, isolates, mixtures, and testing separate.
17 exact rows / 11 sourcesSafety terms keep risk, population, product, and co-exposure context visible.
380 exact rows / 324 sourcesStudy-context terms explain dose, route, formulation, timing, and endpoint.
311 exact rows / 219 sourcesEvidence-Dense Terms
Terms already connected to approved rows
A valid conclusion when sources are absent, too narrow, inconsistent, or indirect.
635 exact rows / 487 sources Evidence method Mechanistic evidenceEvidence about plausible biological pathways, not proof of consumer benefit.
382 exact rows / 325 sources Safety Adverse eventA safety observation reported in a source, with context about population and product.
369 exact rows / 323 sources Study context FormulationProduct form, carrier, purity, and mixture details that affect evidence scope.
201 exact rows / 168 sources Evidence method Human evidenceEvidence from studies involving human participants, kept separate from preclinical and mechanistic evidence.
114 exact rows / 82 sources Evidence method RCTRandomized controlled trial; one study-design term used in evidence summaries.
73 exact rows / 43 sources Evidence method Preclinical evidenceAnimal, cellular, biochemical, or mechanistic work that must stay distinct from human outcomes.
71 exact rows / 56 sources Study context Route of administrationHow oral, inhaled, topical, sublingual, and other routes change interpretation.
70 exact rows / 59 sourcesA-Z Dictionary
Priority terms
Current Public Collections
Browse the live evidence vocabulary
Compounds
Cannabinoids, endocannabinoids, related lipids, commercial compounds, and compound variants.
Targets
Receptors, channels, enzymes, and other biological targets currently represented on the site.
Outcomes
Measured outcomes and endpoints used by source-backed evidence rows.
Safety
Interaction, adverse-event, impairment, pregnancy, pediatric, and higher-risk context pages.
Pathways
Biological mechanisms and signaling systems connected to cannabinoid research.
Deep Reviews
Longer evidence reviews generated from completed workbench research packages.
Next Dictionary Terms
Priority non-entity definitions
| Term | Category | Why it matters | Exact rows | Status |
|---|---|---|---|---|
| Adverse event | Safety | A safety observation reported in a source, with context about population and product. | 369 | Definition page |
| Agonist | Mechanism concept | Receptor-language term for activating a target in a defined model. | 0 | Definition page |
| Allosteric modulator | Mechanism concept | Mechanism term for changing signaling through a site other than the main binding site. | 0 | Definition page |
| Antagonist | Mechanism concept | Receptor-language term for blocking or reducing activation in a defined model. | 0 | Definition page |
| Bioavailability | Pharmacology | How much of a compound reaches circulation or a target tissue after a given route. | 0 | Definition page |
| Broad spectrum | Product identity | Product-language term that needs formulation, testing, and THC-context links. | 1 | Definition page |
| Certificate of analysis | Product identity | Product-testing record that belongs near quality, contaminant, and labeling evidence. | 0 | Definition page |
| Dose | Study context | Amount, timing, frequency, and formulation context behind a source-backed row. | 40 | Definition page |
| Drug interaction | Safety | A safety topic connecting cannabinoids with medicines, enzymes, or clinical monitoring. | 11 | Definition page |
| Entourage effect | Mechanism concept | Common cannabinoid concept that needs careful source-linked explanation. | 0 | Definition page |
| Formulation | Study context | Product form, carrier, purity, and mixture details that affect evidence scope. | 201 | Definition page |
| Full spectrum | Product identity | Product-language term that needs clear separation from isolated-compound evidence. | 0 | Definition page |
| Human evidence | Evidence method | Evidence from studies involving human participants, kept separate from preclinical and mechanistic evidence. | 114 | Definition page |
| Insufficient evidence | Evidence method | A valid conclusion when sources are absent, too narrow, inconsistent, or indirect. | 635 | Definition page |
| Isolate | Product identity | Single-compound product language that should not be mixed with extract evidence. | 16 | Definition page |
| Mechanistic evidence | Evidence method | Evidence about plausible biological pathways, not proof of consumer benefit. | 382 | Definition page |
| Observational study | Evidence method | Human research design that observes associations without randomized assignment. | 10 | Definition page |
| Partial agonist | Mechanism concept | Receptor-language term that needs context about model, target, and comparator. | 0 | Definition page |
| Pharmacodynamics | Pharmacology | What a compound does at receptors, enzymes, channels, pathways, or tissues. | 3 | Definition page |
| Pharmacokinetics | Pharmacology | How a compound is absorbed, distributed, metabolized, and eliminated. | 21 | Definition page |
| Preclinical evidence | Evidence method | Animal, cellular, biochemical, or mechanistic work that must stay distinct from human outcomes. | 71 | Definition page |
| RCT | Evidence method | Randomized controlled trial; one study-design term used in evidence summaries. | 73 | Definition page |
| Receptor binding | Mechanism concept | Evidence language for interaction with a target, not automatic clinical effect. | 9 | Definition page |
| Route of administration | Study context | How oral, inhaled, topical, sublingual, and other routes change interpretation. | 70 | Definition page |
Dictionary Standard
Definitions should point back to evidence, not replace it.
Each future term page should explain the plain-language meaning, show where the term appears in the encyclopedia, separate human and preclinical contexts, and link readers into the source-backed pages that carry the actual claims.